| 1 |
22805229 | A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice. | 2012 Jul-Aug |
1 |
| 2 |
20225994 | Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor. | 2010 May |
6 |
| 3 |
20642448 | Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans. | 2010 Aug |
2 |
| 4 |
21095464 | Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. | 2010 |
1 |
| 5 |
19922897 | Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. | 2009 Oct |
4 |
| 6 |
18303486 | Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. | 2008 Jan-Feb |
5 |
| 7 |
18679669 | Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. | 2008 Oct |
1 |
| 8 |
18989992 | Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. | 2008 |
6 |
| 9 |
17894650 | Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. | 2007 Fall |
1 |
| 10 |
16790555 | Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation. | 2006 Nov |
3 |
| 11 |
15090932 | Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. | 2004 Jan-Feb |
1 |
| 12 |
12584150 | Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. | 2003 Mar |
1 |
| 13 |
12787259 | Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone). | 2003 Jun |
2 |
| 14 |
12848585 | Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. | 2003 |
2 |
| 15 |
14517707 | Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. | 2003 Nov |
3 |
| 16 |
14615471 | Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. | 2003 Dec |
1 |
| 17 |
12236793 | Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. | 2002 Sep-Oct |
4 |